{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:46Z","timestamp":1790739466578,"version":"4.1.0"},"reference-count":194,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is an aggressive disease with limited treatment response and devastating prognosis. Exposure to asbestos and chronic inflammation are acknowledged as main risk factors. Since immune therapy evolved as a promising novel treatment modality, we want to reevaluate and summarize the role of the inflammatory system in MPM. This review focuses on local tumor associated inflammation on the one hand and systemic inflammatory markers, and their impact on MPM outcome, on the other hand. Identification of new biomarkers helps to select optimal patient tailored therapy, avoid ineffective treatment with its related side effects and consequently improves patient\u2019s outcome in this rare disease. Additionally, a better understanding of the tumor promoting and tumor suppressing inflammatory processes, influencing MPM pathogenesis and progression, might also reveal possible new targets for MPM treatment. After reviewing the currently available literature and according to our own research, it is concluded that the suppression of the specific immune system and the activation of its innate counterpart are crucial drivers of MPM aggressiveness translating to poor patient outcome.<\/jats:p>","DOI":"10.3390\/cancers13040658","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T20:51:51Z","timestamp":1612817511000},"page":"658","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Biomarkers for Malignant Pleural Mesothelioma\u2014A Novel View on Inflammation"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-5417","authenticated-orcid":false,"given":"Melanie","family":"Vogl","sequence":"first","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rosenmayr","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Bohanes","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Scheed","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos","family":"Brndiar","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Stubenberger","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-5643","authenticated-orcid":false,"given":"Bahil","family":"Ghanim","sequence":"additional","affiliation":[{"name":"Department of General and Thoracic Surgery, Karl Landsteiner University of Health Sciences, University Hospital Krems, 3500 Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.21037\/jtd.2017.10.16","article-title":"Surgery for malignant pleural mesothelioma: An international guidelines review","volume":"10","author":"Ricciardi","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ichiki, Y., Goto, H., Fukuyama, T., and Nakanishi, K. (2020). Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072153"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Opitz","year":"2020","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"ref_5","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br. J. Ind. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1038\/s41598-017-16551-7","article-title":"Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma","volume":"7","author":"Klikovits","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: A multicenter study","volume":"112","author":"Ghanim","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bjc.2013.815","article-title":"Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma","volume":"110","author":"Ghanim","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","article-title":"Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: A retrospective multicenter analysis","volume":"256","author":"Ghanim","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_12","first-page":"516","article-title":"Inflammation in malignant mesothelioma\u2014friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years\u2019 Experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chiarucci, C., Cannito, S., Daffin\u00e0, M.G., Amato, G., Giacobini, G., Cutaia, O., Lofiego, M.F., Fazio, C., Giannarelli, D., and Danielli, R. (2020). Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. Cancers, 12.","DOI":"10.3390\/cancers12020361"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Zimmerman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"Jama Oncol."},{"key":"ref_19","first-page":"502","article-title":"FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology (Williston Park)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.thorsurg.2020.08.003","article-title":"Preoperative Identification of Benefit from Surgery for Malignant Pleural Mesothelioma","volume":"30","author":"Opitz","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2011.121","article-title":"Predictive biomarkers: A paradigm shift towards personalized cancer medicine","volume":"8","author":"Kerr","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Scherpereel, A., Opitz, I., Berghmans, T., Psallidas, I., Glatzer, M., Rigau, D., Astoul, P., Bolukbas, S., Boyd, J., and Coolen, J. (2020). ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J., 55.","DOI":"10.1183\/13993003.00953-2019"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103753","DOI":"10.1016\/j.cellimm.2018.01.013","article-title":"Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?","volume":"343","author":"Badalamenti","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"ref_26","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"South. Afr. Med. J. Suid-Afrik. Tydskr. Vir Geneeskd."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Minnema-Luiting, J., Vroman, H., Aerts, J., and Cornelissen, R. (2018). Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041041"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother. Cii"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Veltman, J.D., Lambers, M.E., van Nimwegen, M., Hendriks, R.W., Hoogsteden, H.C., Aerts, J.G., and Hegmans, J.P. (2010). COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-464"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: Correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thx.2003.008912","article-title":"Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma","volume":"59","author":"Baldi","year":"2004","journal-title":"Thorax"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejcts.2010.02.012","article-title":"May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?","volume":"38","author":"Mineo","year":"2010","journal-title":"Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg."},{"key":"ref_41","first-page":"1857","article-title":"Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma","volume":"8","author":"Edwards","year":"2002","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.ejca.2005.04.019","article-title":"Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma","volume":"41","author":"Cawkwell","year":"2005","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cedr\u00e9s, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., and Felip, E. (2015). Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121071"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cornelissen, R., Lievense, L.A., Maat, A.P., Hendriks, R.W., Hoogsteden, H.C., Bogers, A.J., Hegmans, J.P., and Aerts, J.G. (2014). Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106742"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Blondy, T., d\u2019Almeida, S.M., Briolay, T., Tabiasco, J., Meiller, C., Ch\u00e9n\u00e9, A.L., Cellerin, L., Deshayes, S., Delneste, Y., and Fonteneau, J.F. (2020). Involvement of the M-CSF\/IL-34\/CSF-1R pathway in malignant pleural mesothelioma. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2019-000182"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum. Pathol."},{"key":"ref_47","first-page":"1036","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.lungcan.2015.03.013","article-title":"Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma","volume":"88","author":"Cornelissen","year":"2015","journal-title":"Lung Cancer (Amst. Neth.)"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: A review","volume":"234","author":"Najafi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/08977199409015049","article-title":"Transforming growth factor-beta: Antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma","volume":"11","author":"Fitzpatrick","year":"1994","journal-title":"Growth Factors (ChurSwitz.)"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/bjc.2012.519","article-title":"Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells","volume":"107","author":"Hoda","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2016.04.018","article-title":"Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma\u2014A multi-institutional study","volume":"63","author":"Hoda","year":"2016","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-12-1103","article-title":"Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma","volume":"12","author":"Nuvoli","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_56","first-page":"3696","article-title":"Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effects of a COX-2 inhibitor","volume":"60","author":"Marrogi","year":"2000","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","article-title":"Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network","volume":"179","author":"Li","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/carcin\/bgy018","article-title":"FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal","volume":"39","author":"Schelch","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Vlacic, G., Hoda, M.A., Klikovits, T., Sinn, K., Gschwandtner, E., Mohorcic, K., Schelch, K., Pirker, C., Peter-Vorosmarty, B., and Brankovic, J. (2019). Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity. Cells, 8.","DOI":"10.3390\/cells8091091"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ghahremanifard, P., Chanda, A., Bonni, S., and Bose, P. (2020). TGF-beta Mediated Immune Evasion in Cancer-Spotlight on Cancer-Associated Fibroblasts. Cancers, 12.","DOI":"10.3390\/cancers12123650"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: A review","volume":"234","author":"Najafi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1389450119666180803121737","article-title":"Celecoxib in Cancer Therapy and Prevention\u2014Review","volume":"20","author":"Nowaszewska","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.21037\/tcr.2018.11.22","article-title":"The role of celecoxib for colorectal cancer treatment: A systematic review","volume":"7","author":"Zhou","year":"2018","journal-title":"Transl. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/COC.0000000000000465","article-title":"A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer","volume":"41","author":"Chen","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.7150\/jca.35003","article-title":"Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis","volume":"11","author":"Zhang","year":"2020","journal-title":"J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.2147\/DDDT.S169627","article-title":"Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer","volume":"12","author":"Yi","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.lungcan.2014.08.005","article-title":"Effect of NSAIDS and COX-2 inhibitors on the incidence and severity of asbestos-induced malignant mesothelioma: Evidence from an animal model and a human cohort","volume":"86","author":"Robinson","year":"2014","journal-title":"Lung Cancer (Amst. Neth.)"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41379-020-0534-z","article-title":"Prognostic value of macrophage polarization markers in epithelial neoplasms and melanoma. A systematic review and meta-analysis","volume":"33","author":"Hardisson","year":"2020","journal-title":"Mod. Pathol. Off. J. United States Can. Acad. Pathol. Inc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ijc.11710","article-title":"Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention","volume":"109","author":"Catalano","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood.V74.3.940.940","article-title":"Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro","volume":"74","author":"Demetri","year":"1989","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"ref_74","first-page":"1765","article-title":"Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages","volume":"11","author":"Blondy","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ijc.2910510220","article-title":"Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: Interleukin-6 production as a common feature","volume":"51","author":"Schmitter","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_77","first-page":"883","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Blanquart","year":"2012","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_78","first-page":"755","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): A brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kishimoto, T., Fujimoto, N., Ebara, T., Omori, T., Oguri, T., Niimi, A., Yokoyama, T., Kato, M., Usami, I., and Nishio, M. (2019). Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients. Bmc Cancer, 19.","DOI":"10.1186\/s12885-019-6419-1"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mds647","article-title":"Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer","volume":"24","author":"Zielinski","year":"2013","journal-title":"Ann. Oncol"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.18632\/oncotarget.23580","article-title":"Prognostic value of PD -L1 expression in patients with primary solid tumors","volume":"9","author":"Xiang","year":"2018","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","article-title":"Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: The impact of C-reactive protein and immune-checkpoint inhibition","volume":"10","author":"Ghanim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_84","first-page":"1758835919870360","article-title":"The evolving immuno-oncology landscape in advanced lung cancer: First-line treatment of non-small cell lung cancer","volume":"11","author":"Low","year":"2019","journal-title":"Adv. Med. Oncol."},{"key":"ref_85","first-page":"1758835920962362","article-title":"PD-L1 and prognosis in patients with malignant pleural mesothelioma: A meta-analysis and bioinformatics study","volume":"12","author":"Jin","year":"2020","journal-title":"Adv. Med. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"White, M.G., Schulte, J.J., Xue, L., Berger, Y., Schuitevoerder, D., Vining, C.C., Kindler, H.L., Husain, A., Turaga, K.K., and Eng, O.S. (2020). Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br. J. Cancer.","DOI":"10.1038\/s41416-020-01130-x"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in Malignant Pleural Mesothelioma","volume":"10","author":"Borm","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00432-020-03457-7","article-title":"Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: Potential implications in the immune response and prognosis","volume":"147","author":"Carosio","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Yang, H., Hall, S.R.R., Sun, B., and Yao, F. (2020). Comment on \u201cHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy\u201d. Br. J. Cancer.","DOI":"10.1038\/s41416-020-01214-8"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Yang, H., Xu, D., Yang, Z., Yao, F., Zhao, H., Schmid, R.A., and Peng, R.W. (2020). Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 12.","DOI":"10.3390\/cancers12082310"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1758835920971421","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.clgc.2018.01.010","article-title":"Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis","volume":"16","author":"Lubas","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_95","first-page":"988","article-title":"Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer","volume":"5","author":"McRae","year":"2010","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Liu, Y., Chen, S., Zheng, C., Ding, M., Zhang, L., Wang, L., Xie, M., and Zhou, J. (2017). The prognostic value of the preoperative c-reactive protein\/albumin ratio in ovarian cancer. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3220-x"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4103\/1008-682X.123686","article-title":"Prognostic role of C-reactive protein in prostate cancer: A systematic review and meta-analysis","volume":"16","author":"Liu","year":"2014","journal-title":"Asian J. Androl."},{"key":"ref_98","first-page":"1494","article-title":"Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: A systematic review and meta-analysis","volume":"44","author":"Lin","year":"2018","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Liu, Z., Shi, H., and Chen, L. (2019). Prognostic role of pre-treatment C-reactive protein\/albumin ratio in esophageal cancer: A meta-analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6373-y"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12199-016-0530-6","article-title":"Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Tanrikulu","year":"2016","journal-title":"Environ. Health Prev. Med."},{"key":"ref_101","first-page":"587","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_102","first-page":"445","article-title":"Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma","volume":"32","author":"Otoshi","year":"2018","journal-title":"Vivo (Athens Greece)"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/bjc.2013.504","article-title":"Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma","volume":"109","author":"Meniawy","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","article-title":"Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems","volume":"55","author":"Edwards","year":"2000","journal-title":"Thorax"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.21037\/jtd.2016.07.55","article-title":"Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma","volume":"8","author":"Sandri","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_109","first-page":"249","article-title":"Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma","volume":"11","author":"Krug","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4149\/neo_2017_114","article-title":"Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma","volume":"64","author":"Zhang","year":"2017","journal-title":"Neoplasma"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.1989.7.8.1157","article-title":"Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients","volume":"7","author":"Ruffie","year":"1989","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jtcvs.2012.09.023","article-title":"Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and\/or pleurodesis","volume":"145","author":"Baud","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"32171","DOI":"10.18632\/oncotarget.16291","article-title":"Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: A systematic review and meta-analysis","volume":"8","author":"Bowen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"21861","DOI":"10.18632\/oncotarget.25076","article-title":"Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome","volume":"9","author":"Janik","year":"2018","journal-title":"Oncotarget"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: A systematic review and meta-analysis","volume":"19","author":"Ethier","year":"2017","journal-title":"Breast Cancer Res. Bcr"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jso.24523","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review","volume":"115","author":"Haram","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer (Amst. Neth.)"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Kiriu, T., Yamamoto, M., Nagano, T., Hazama, D., Sekiya, R., Katsurada, M., Tamura, D., Tachihara, M., Kobayashi, K., and Nishimura, Y. (2018). The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193018"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1245\/s10434-015-4869-5","article-title":"Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis","volume":"23","author":"Yodying","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/icvts\/ivv206","article-title":"Elevated inflammatory parameters and inflammation scores are associated with poor prognosis in patients undergoing pulmonary metastasectomy for colorectal cancer","volume":"21","author":"Ghanim","year":"2015","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_122","first-page":"1923","article-title":"Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"31926","DOI":"10.18632\/oncotarget.7876","article-title":"Prognostic role of lymphocyte to monocyte ratio for patients with cancer: Evidence from a systematic review and meta-analysis","volume":"7","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000499677","article-title":"The Value of COX-2, NF-\u03baB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma","volume":"42","author":"Yin","year":"2019","journal-title":"Oncol. Res. Treat."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2018.04.023","article-title":"Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis","volume":"483","author":"Li","year":"2018","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"32356","DOI":"10.18632\/oncotarget.16020","article-title":"Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term survival in both resected and metastatic colorectal cancer: An updated systematic review and meta-analysis of 24 studies","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/OTT.S154162","article-title":"Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: A comprehensive meta-analysis of 17 cohort studies","volume":"11","author":"Zhou","year":"2018","journal-title":"Oncotargets Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"22618","DOI":"10.1038\/srep22618","article-title":"Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: A systematic review and meta-analysis","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/bjc.1998.150","article-title":"Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma","volume":"77","author":"Nakano","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_131","first-page":"4419","article-title":"Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment","volume":"54","author":"Monti","year":"1994","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_133","first-page":"55","article-title":"The role of interleukin-6 in malignant mesothelioma","volume":"4","author":"Ho","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bjc.1995.71","article-title":"Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer","volume":"71","author":"Scambia","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/sj.bjc.6600956","article-title":"Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients","volume":"88","author":"Bachelot","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"29820","DOI":"10.18632\/oncotarget.25661","article-title":"Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer","volume":"9","author":"Vainer","year":"2018","journal-title":"Oncotarget"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12032-012-0333-6","article-title":"Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer","volume":"30","author":"Hao","year":"2013","journal-title":"Med. Oncol. (Northwood Lond. Engl.)"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/ijc.27892","article-title":"Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy","volume":"132","author":"Chang","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_139","first-page":"3251","article-title":"Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer","volume":"32","author":"Ujiie","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.08.025","article-title":"Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"125","author":"Jia","year":"2018","journal-title":"Lung Cancer (Amst. Neth.)"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"544.e525","DOI":"10.1016\/j.urolonc.2017.05.005","article-title":"Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer","volume":"35","author":"Kallio","year":"2017","journal-title":"Urol. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4110\/in.2020.20.e27","article-title":"Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1\/PD-L1 Inhibitors","volume":"20","author":"Kang","year":"2020","journal-title":"Immune Netw."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"100127","DOI":"10.1016\/j.ctarc.2019.100127","article-title":"Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma","volume":"19","author":"Pilskog","year":"2019","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"Chen","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","volume":"75","author":"Kao","year":"2012","journal-title":"Lung Cancer (Amst. Neth.)"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J. Pathol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/ijc.22006","article-title":"Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas","volume":"119","author":"Adachi","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_149","first-page":"1947","article-title":"VEGF targeting in mesotheliomas using an interleukin-6 signal inhibitor based on adenovirus gene delivery","volume":"30","author":"Adachi","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2020.00126","article-title":"Antiangiogeneic Strategies in Mesothelioma","volume":"10","author":"Nowak","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.52.4.561","article-title":"Serological Reactions in Pneumonia with a Non-Protein Somatic Fraction of Pneumococcus","volume":"52","author":"Tillett","year":"1930","journal-title":"J. Exp. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"48487","DOI":"10.1074\/jbc.R400025200","article-title":"C-reactive Protein","volume":"279","author":"Black","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1007\/s00268-017-3900-3","article-title":"Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer","volume":"41","author":"Ibuki","year":"2017","journal-title":"World J. Surg."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.7314\/APJCP.2013.14.10.5735","article-title":"Prognostic role of C-reactive protein in gastric cancer: A meta-analysis","volume":"14","author":"Yu","year":"2013","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"47090","DOI":"10.18632\/oncotarget.17478","article-title":"Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis","volume":"8","author":"Janik","year":"2017","journal-title":"Oncotarget"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jjco\/hyq159","article-title":"Survival and prognostic factors in malignant pleural mesothelioma: A retrospective study of 314 patients in the west part of Japan","volume":"41","author":"Nojiri","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_160","first-page":"697","article-title":"Health-related quality of life and inflammatory markers in malignant pleural mesothelioma","volume":"21","author":"Kao","year":"2013","journal-title":"Supportive Care Cancer Off. J. Multinatl. Assoc. Supportive Care Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/thoraxjnl-2012-201871","article-title":"Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease","volume":"68","author":"Duvoix","year":"2013","journal-title":"Thorax"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"10i","DOI":"10.1016\/S0002-9149(03)00504-6","article-title":"Utility of inflammatory markers in the management of coronary artery disease","volume":"92","author":"Rosenson","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e993","DOI":"10.6061\/clinics\/2020\/e993","article-title":"Pretreatment plasma fibrinogen level as a prognostic biomarker for patients with lung cancer","volume":"75","author":"Zhang","year":"2020","journal-title":"Clinics (Sao Paulo Braz.)"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e16974","DOI":"10.1097\/MD.0000000000016974","article-title":"Prognostic value of pretreatment plasma fibrinogen in patients with colorectal cancer: A systematic review and meta-analysis","volume":"98","author":"Li","year":"2019","journal-title":"Medicine"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e17310","DOI":"10.1097\/MD.0000000000017310","article-title":"Clinicopathological and prognostic value of preoperative plasma fibrinogen in gastric cancer patients: A meta-analysis","volume":"98","author":"Cheng","year":"2019","journal-title":"Medicine"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ctrv.2015.10.002","article-title":"Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis","volume":"41","author":"Perisanidis","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjc.6605547","article-title":"The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: A multi-centre trial","volume":"102","author":"Seebacher","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"12557","DOI":"10.1038\/s41598-017-12914-2","article-title":"In-trathoracic solitary fibrous tumor\u2014An international multicenter study on clinical outcome and novel circulating biomarkers","volume":"7","author":"Ghanim","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr. J."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5435\/JAAOS-22-03-193","article-title":"Evaluation of malnutrition in orthopaedic surgery","volume":"22","author":"Cross","year":"2014","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"161","DOI":"10.31083\/j.rcm.2019.03.524","article-title":"Serum albumin in patients undergoing transcatheter aortic valve replacement: A meta-analysis","volume":"20","author":"Hsieh","year":"2019","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_172","first-page":"777","article-title":"Is low serum albumin associated with postoperative complications in patients undergoing cardiac surgery?","volume":"21","author":"Karas","year":"2015","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3171\/2018.3.SPINE171183","article-title":"Low preoperative serum prealbumin levels and the postoperative surgical site infection risk in elective spine surgery: A consecutive series","volume":"29","author":"Salvetti","year":"2018","journal-title":"J. Neurosurg. Spine"},{"key":"ref_174","first-page":"340","article-title":"Serum Levels of Prealbumin and Albumin for Preoperative Risk Stratification","volume":"34","author":"Loftus","year":"2019","journal-title":"Nutr. Clin. Pract. Off. Publ. Am. Soc. Parenter. Enter. Nutr."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1007\/s13277-014-1938-5","article-title":"Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma","volume":"35","author":"Yao","year":"2014","journal-title":"Tumour Biol. J. Int. Soc. Oncodev. Biol. Med."},{"key":"ref_176","first-page":"288","article-title":"Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery","volume":"14","author":"Harris","year":"2019","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_177","first-page":"573","article-title":"A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7861\/clinmedicine.9-1-30","article-title":"Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein\/albumin ratio as a predictor of patient outcome","volume":"9","author":"Fairclough","year":"2009","journal-title":"Clin. Med. (Lond. Engl.)"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Ranzani, O.T., Zampieri, F.G., Forte, D.N., Azevedo, L.C., and Park, M. (2013). C-reactive protein\/albumin ratio predicts 90-day mortality of septic patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059321"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jgh.14442","article-title":"C-reactive protein\/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer","volume":"34","author":"Kudou","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_182","first-page":"1559325820931290","article-title":"Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis","volume":"18","author":"Xie","year":"2020","journal-title":"Dose-Response A Publ. Int. Hormesis Soc."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e13505","DOI":"10.1097\/MD.0000000000013505","article-title":"The prognostic value of C-reactive protein to albumin ratio in patients with lung cancer","volume":"97","author":"Deng","year":"2018","journal-title":"Medicine"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e16064","DOI":"10.1097\/MD.0000000000016064","article-title":"Prognostic role of C-reactive protein to albumin ratio in colorectal cancer: A meta analysis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1245\/s10434-018-6385-x","article-title":"The C-Reactive Protein\/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study","volume":"25","author":"Takamori","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.ejim.2016.07.020","article-title":"The beneficial effect of acute phase increase in serum ferritin","volume":"35","author":"Thachil","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation","volume":"29","author":"Kernan","year":"2017","journal-title":"Int. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Hsu, M.Y., Mina, E., Roetto, A., and Porporato, P.E. (2020). Iron: An Essential Element of Cancer Metabolism. Cells, 9.","DOI":"10.3390\/cells9122591"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.freeradbiomed.2018.10.401","article-title":"Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention","volume":"133","author":"Toyokuni","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5606\/tgkdc.dergisi.2019.17557","article-title":"Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos","volume":"27","author":"Benli","year":"2019","journal-title":"Turk. Gogus Kalp Damar Cerrahisi Derg."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"902748","DOI":"10.1155\/2014\/902748","article-title":"Oxidative status and acute phase reactants in patients with environmental asbestos exposure and mesothelioma","volume":"2014","author":"Sezgi","year":"2014","journal-title":"Sci. World J."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/path.4075","article-title":"Iron overload signature in chrysotile-induced malignant mesothelioma","volume":"228","author":"Jiang","year":"2012","journal-title":"J. Pathol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cas.13460","article-title":"Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats","volume":"109","author":"Ohara","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3389\/fimmu.2017.01559","article-title":"Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth","volume":"8","author":"Agostinis","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/658\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:20:38Z","timestamp":1760160038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/4\/658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":194,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["cancers13040658"],"URL":"https:\/\/doi.org\/10.3390\/cancers13040658","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,6]]}}}